{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T11:02:22Z","timestamp":1750503742996,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s10549-020-05559-9","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T19:02:21Z","timestamp":1581102141000},"page":"423-428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Neoadjuvant therapy and sentinel lymph node biopsy in HER2-positive breast cancer patients: results from the PEONY trial"],"prefix":"10.1007","volume":"180","author":[{"given":"Xiao","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Er","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao-Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Qiang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin-Bin","family":"Cong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6252-684X","authenticated-orcid":false,"given":"Yong-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Min","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"5559_CR1","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","volume":"15","author":"B Fisher","year":"1997","unstructured":"Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483\u20132493. https:\/\/doi.org\/10.1200\/JCO.1997.15.7.2483","journal-title":"J Clin Oncol"},{"key":"5559_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3692","author":"Z Shao","year":"2019","unstructured":"Shao Z, Pang D, Yang H et al (2019) Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY Phase 3 Randomized Clinical Trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3692","journal-title":"JAMA Oncol"},{"key":"5559_CR3","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1007\/s00268-012-1635-8","volume":"36","author":"A Kumar","year":"2012","unstructured":"Kumar A, Puri R, Gadgil PV et al (2012) Sentinel lymph node biopsy in primary breast cancer: window to management of the axilla. World J Surg 36:1453\u20131459. https:\/\/doi.org\/10.1007\/s00268-012-1635-8","journal-title":"World J Surg"},{"key":"5559_CR4","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1245\/s10434-017-6085-y","volume":"24","author":"LF Gentile","year":"2017","unstructured":"Gentile LF, Plitas G, Zabor EC et al (2017) Tumor biology predicts pathologic complete response to neoadjuvant chemotherapy in patients presenting with locally advanced breast cancer. Ann Surg Oncol 24:3896\u20133902. https:\/\/doi.org\/10.1245\/s10434-017-6085-y","journal-title":"Ann Surg Oncol"},{"key":"5559_CR5","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","volume":"260","author":"JC Boughey","year":"2014","unstructured":"Boughey JC, McCall LM, Ballman KV et al (2014) Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial. Ann Surg 260:608\u2013614. https:\/\/doi.org\/10.1097\/SLA.0000000000000924","journal-title":"Ann Surg"},{"key":"5559_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowshi T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(11)70336-9","journal-title":"Lancet Oncol"},{"key":"5559_CR7","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L et al (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 318:918\u2013926. https:\/\/doi.org\/10.1001\/jama.2017.11470","journal-title":"JAMA"},{"key":"5559_CR8","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME et al (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15:1303\u20131310. https:\/\/doi.org\/10.1016\/S1470-2045(14)70460-7","journal-title":"Lancet Oncol"},{"key":"5559_CR9","unstructured":"Grasishar WJ, Anderson BO, Balassanian R et al (2017) Breast Cancer, Version 3.2017 featured updates to the NCCN Guidelines. National Comprehensive Cancer Network. https:\/\/www.NCCN.org. Accessed 10 Nov 2017"},{"key":"5559_CR10","unstructured":"Grasishar WJ, Anderson BO, Balassanian R et al (2020) Breast Cancer, Version 1.2020 featured updates to the NCCN Guidelines. National Comprehensive Cancer Network. https:\/\/www.NCCN.org. Accessed 15\u00a0Jan 2020"},{"issue":"7","key":"5559_CR11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1093\/annonc\/mdy537","volume":"30","author":"G. Curigliano","year":"2019","unstructured":"Curigliano G, Burstein H, Winer E et al (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer. Ann Oncol 28:1700\u20131712. https:\/\/doi.org\/10.1093\/annonc\/mdy537","journal-title":"Annals of Oncology"},{"key":"5559_CR12","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdz235","volume":"30","author":"HJ Burstein","year":"2019","unstructured":"Burstein HJ, Curigliano G, Loibl S et al (2019) Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 30:1541\u20131557. https:\/\/doi.org\/10.1093\/annonc\/mdz235","journal-title":"Ann Oncol"},{"key":"5559_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang C-S, Mano MS et al (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617\u2013628. https:\/\/doi.org\/10.1056\/NEJMoa1814017","journal-title":"N Engl J Med"},{"key":"5559_CR14","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/tbj.13422","volume":"25","author":"ZQ Shi","year":"2019","unstructured":"Shi ZQ, Qiu PF, Liu YB et al (2019) Neoadjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer. Breast J 25:1154\u20131159. https:\/\/doi.org\/10.1111\/tbj.13422","journal-title":"Breast J"},{"key":"5559_CR15","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa012782","volume":"349","author":"U Veronesi","year":"2003","unstructured":"Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546\u2013553. https:\/\/doi.org\/10.1056\/NEJMoa012782","journal-title":"N Engl J Med"},{"key":"5559_CR16","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","volume":"11","author":"DN Krag","year":"2010","unstructured":"Krag DN, Anderson SJ, Julian TB et al (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11:927\u2013933. https:\/\/doi.org\/10.1016\/S1470-2045(10)70207-2","journal-title":"Lancet Oncol"},{"key":"5559_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/jnci\/djj158","volume":"98","author":"RE Mansel","year":"2006","unstructured":"Mansel RE, Fallowfield L, Kissin M et al (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98:599\u2013609. https:\/\/doi.org\/10.1093\/jnci\/djj158","journal-title":"J Natl Cancer Inst"},{"key":"5559_CR18","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) Clinical Trial. JAMA 310:1455\u20131461. https:\/\/doi.org\/10.1001\/jama.2013.278932","journal-title":"JAMA"},{"key":"5559_CR19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T et al (2013) Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENATINA): a prospective, multicentre cohort study. Lancet Oncol 14:609\u2013618. https:\/\/doi.org\/10.1016\/S1470-2045(13)70166-9","journal-title":"Lancet Oncol"},{"key":"5559_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M et al (2015) Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 33:258\u2013264. https:\/\/doi.org\/10.1200\/JCO.2014.55.7827","journal-title":"J Clin Oncol"},{"key":"5559_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.amjsurg.2016.07.018","volume":"212","author":"CH El Hage","year":"2016","unstructured":"El Hage CH, Headon H, El Tokhy O et al (2016) Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. Am J Surg 212:969\u2013981. https:\/\/doi.org\/10.1016\/j.amjsurg.2016.07.018","journal-title":"Am J Surg"},{"key":"5559_CR22","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/SLA.0b013e3181b8fd5e","volume":"250","author":"KK Hunt","year":"2009","unstructured":"Hunt KK, Yi M, Mittendorf EA et al (2009) Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 250:558\u2013566. https:\/\/doi.org\/10.1097\/SLA.0b013e3181b8fd5e","journal-title":"Ann Surg"},{"key":"5559_CR23","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/1097-0142(20001201)89:11<2187::AID-CNCR6>3.0.CO;2-#","volume":"89","author":"KS Nason","year":"2000","unstructured":"Nason KS, Anderson BO, Byrd DR et al (2000) Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 89:2187\u20132194","journal-title":"Cancer"},{"key":"5559_CR24","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34:1072\u20131078. https:\/\/doi.org\/10.1200\/JCO.2015.64.0094","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05559-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-020-05559-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-020-05559-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T22:26:04Z","timestamp":1612823164000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-020-05559-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["5559"],"URL":"https:\/\/doi.org\/10.1007\/s10549-020-05559-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"type":"print","value":"0167-6806"},{"type":"electronic","value":"1573-7217"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"20 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the Ethical Standards of the Institutional Research Committee and\/or National Research Committee (National Medical Products Administrator 2015L01504, Fudan University Shanghai Cancer Center 150915\u20132, Shandong Cancer Hospital Affiliated to Shandong University 201512002) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}